論文 - 河上 洋
-
Hasuike S, Nagata K, Sasaki H, Hirata T, Suzuki S, Komaki Y, Ozono Y, Nakamura K, Miike T, Iwakiri H, Sueta M, Yamamoto S, Maekawa K, Kawakami H
Internal medicine (Tokyo, Japan) 62 ( 21 ) 3143 - 3149 2023年11月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本内科学会
We reported a notable case of inflammatory hepatocellular adenoma that grew during pregnancy, consequently changing its appearance on magnetic resonance imaging remarkably. A 5-months-pregnant 35-year-old woman presented with a 37-mm liver nodule that had been diagnosed as focal nodular hyperplasia 3 years earlier. She had never used oral contraceptives. After 2 months, the nodule grew to 57 mm. The patient delivered a full-term infant without complications. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging performed after delivery revealed markedly different findings compared with the first images. A liver biopsy was performed, and the tumor was diagnosed as inflammatory hepatocellular adenoma.
-
Ozono Y, Kawakami H, Uchiyama N, Hatada H, Ogawa S
Journal of Gastroenterology 58 ( 11 ) 1081 - 1093 2023年11月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Gastroenterology
Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary–pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary–pancreatic cancers using EUS-FNA/FNB specimens.
-
Kai K, Nakashima K, Kawakami H, Takeno S, Hishikawa Y, Ikenoue M, Hamada T, Imamura N, Shibata T, Noritomi T, Sasaki F, Nakamura Y, Nanashima A
Internal medicine (Tokyo, Japan) advpub ( 0 ) 903 - 910 2023年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本内科学会
<b>Introduction </b>Photodynamic therapy (PDT) is a salvage treatment for local failure after chemoradiotherapy for esophageal cancer. Salvage PDT is the treatment available for vulnerable patients with various comorbidities at risk of salvage esophagectomy. This study assessed the impact of the Charlson comorbidity index (CCI) on the outcomes of salvage PDT using talaporfin sodium (TS) for esophageal cancer. <b>Patients and methods </b>Consecutive patients with esophageal cancer who underwent salvage TS-PDT from 2016 to 2022 were included in this retrospective study. We investigated the local complete response (L-CR), progression-free survival (PFS) and overall survival (OS) and evaluated the relationship between the CCI and therapeutic efficacy. <b>Results </b>In total, 25 patients were enrolled in this study. Overall, 12 patients (48%) achieved an L-CR, and the 2-year PFS and OS rates were 24.9% and 59.4%, respectively. In a multivariate analysis, a CCI ≥1 (p=0.041) and deeper invasion (p=0.048) were found to be significant independent risk factors for not achieving an L-CR. To evaluate the efficacy associated with comorbidities, we divided the patients into the CCI=0 group (n=11) and the CCI ≥1 group (n=14). The rate of an L-CR (p=0.035) and the 2-year PFS (p=0.029) and OS (p=0.018) rates in the CCI ≥1 group were significantly lower than those in the CCI=0 group. <b>Conclusion </b>This study found that the CCI was negatively associated with the efficacy of salvage TS-PDT for esophageal cancer.
-
Newly developed dedicated guide sheath system for selective pancreatobiliary biopsy 査読あり
Kawakami H, Uchiyama N, Hatada H
Digestive Endoscopy 35 ( 5 ) e100 - e102 2023年7月
担当区分：筆頭著者, 責任著者 記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Digestive Endoscopy
DOI： 10.1111/den.14593
-
食道亜全摘術の胃管吻合完全閉塞に対しランデブー内視鏡法にて再開通した１例 査読あり
鈴木 翔, 河上 洋, 三池 忠, 内田 圭佑, 田村 穂高, 吉田 直樹, 内山 尚美, 小川 宗一郎, 畑田 紘志, 田代 耕盛
日本消化器内視鏡学会雑誌 65 ( 2 ) 117 - 124 2023年
担当区分：責任著者 記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本消化器内視鏡学会
症例は76歳，男性．食道胃接合部癌に対し食道亜全摘術および胃管再建術を施行された．術後７日目に嚥下障害がみられ，各種検査により吻合部の完全閉塞と診断した．対側の食道粘膜を巻き込むように縫合したことが原因と考えられ，口側および胃側からの内視鏡的アプローチ（ランデブー内視鏡法）を試みる方針とした．全身麻酔下に手術時の腹部創より胃管を小切開して胃側内視鏡の挿入経路を確保した．完全閉塞部は各々の内視鏡の透過光が対側の内視鏡で確認された．ESDナイフ（Hook knife-J）で閉塞部を切開後，ガイドワイヤを挿入し，バルーンカテーテルで拡張術を行い，偶発症はなく終了した．術後食道完全閉塞に対してはランデブー内視鏡法により外科的再吻合術を回避し得る可能性がある．
DOI： 10.11280/gee.65.117
-
悪性遠位胆管閉塞に対するフルカバー付き金属ステント留置の際のアンカリングプラスチックステント先行留置による開存期間延長効果
河上 洋
日本消化器内視鏡学会雑誌 65 ( 9 ) 1498 - 1498 2023年
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本消化器内視鏡学会
【背景】悪性遠位胆管閉塞に対するフルカバー付き金属ステント（fully covered self-expandable metal stents：FCSEMSs）は汎用されている．本研究目的は悪性遠位胆管閉塞に対するFCSEMS留置時のアンカリング用プラスチックステントの有用性を検討することである．【方法】多施設コホート研究により，悪性遠位胆管閉塞に対するFCSEMS留置時にアンカリングプラスチックステント追加留置の有無の有用性を後方視的に比較した．アンカリングの方法は，選択的胆管挿管後に２本のガイドワイヤを留置した後，7-Frのダブルピッグテールプラスチックステント（double-pigtail plastic stent：DPPS）を先行留置させた．次いでFCSEMSをside-by-sideに留置した．DPPSの近位端はFCSEMSを跨ぐように，10cm以上のステントを選択した．FCSEMS長は内視鏡医が選択した．【結果】185例中120例がDPPS留置の併施（アンカリング群），65例がFCSEMS単独留置（単独群）であった．基礎疾患は両群ともに膵癌がもっとも多かった（72.5 vs 80％，NS）．FCSEMS長は５ or ６cmが多く，ステント開存期間中央値はアンカリング併施群で単独群と比較して有意に延長した（342日 vs 240日，<i>P</i>＝0.04）．ステント迷入はアンカリング併施群で単独群と比較して有意に少なかった（10.8％ vs 27.7％，<i>P</i>＝0.01）．ステント閉塞や偶発症（膵炎，胆嚢炎など）は両群間で有意差は認められなかった．【結語】DPPSによるアンカリングはシンプルな方法でありながらFCSEMSの開存期間を延長させるだけでなく，偶発症も増加しなかった．FCSEMSの迷入リスクを減少させる可能性も示唆された．
DOI： 10.11280/gee.65.1498
-
鈴木 翔, 河上 洋, 三池 忠
日本消化器内視鏡学会雑誌 65 ( 10 ) 2145 - 2158 2023年
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本消化器内視鏡学会
消化器内視鏡は消化器診療において必要不可欠な医療機器で，検査・診断のみならず治療でも大きな役割を担っている．ルーチンのEGDや全大腸内視鏡検査（total colonoscopy：TCS）の他，胆膵内視鏡，EUS，ESDや止血処置・異物除去など内視鏡スキルは多岐に渡るが，内視鏡技術を向上させるには経験と時間が必要である．現在，様々なタイプのトレーニングモデルやシミュレーターが開発されており，初学者の練習や研修医・学生指導に用いられている．トレーニングモデルは簡便性や低コストが長所で，シミュレーターは豊富な種類の内視鏡検査・手技のトレーニングができる点で優れている．練習や指導の中でトレーニングモデルやシミュレーターを上手に活用して，個々のスキルアップ，実際の内視鏡診療の向上に繋がることが期待される．
DOI： 10.11280/gee.65.2145
-
Duodenoscope insertion difficulty due to perigastric adhesions overcome using an overtube
Kawakami H., Uchiyama N., Ogawa S.
Journal of Hepato-Biliary-Pancreatic Sciences 30 ( 12 ) e84 - e85 2023年
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Hepato-Biliary-Pancreatic Sciences
DOI： 10.1002/jhbp.1362
-
Klebsiella pneumoniaeによる侵襲性肝膿瘍症候群を発症し、眼内炎から失明に至った1例
田村 穂高，大園 芳範，内山 尚美，畑田 紘志，中村 憲一，岩切 久芳，蓮池 悟，永田 賢治，河上 洋
日本消化器病学会雑誌 120 ( 6 ) 500 - 507 2023年
担当区分：責任著者 記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Japanese Society of Gastroenterology
An 82-year-old female patient was admitted to our hospital for visual acuity loss in both eyes. The patient was diagnosed with invasive liver abscess syndrome and bilateral endophthalmitis due to Klebsiella pneumoniae 4 days after the onset of ocular symptoms. The liver abscess improved by broad-spectrum antibiotics and intravitreal injection, but bilateral blindness occurred. Most literature reported fever as the first symptom of invasive abscess syndrome, but this case had no fever at the onset of ocular symptoms. Delayed invasive liver abscess syndrome diagnosis might cause poor visual acuity prognosis.
-
HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma 査読あり
Nakamura T., Hayashi T., Kimura Y., Kawakami H., Takahashi K., Ishiwatari H., Goto T., Motoya M., Yamakita K., Sakuhara Y., Ono M., Tanaka E., Omi M., Murakawa K., Iida T., Sakurai T., Haba S., Abiko T., Ito Y.M., Maguchi H., Hirano S., Nakamura T., Hayashi T., Kimura Y., Kawakami H., Takahashi K., Ishiwatari H., Goto T., Ono M., Tanaka E., Omi M., Murakawa K., Iida T., Sakurai T., Haba S., Abiko T., Ito Y.M., Maguchi H., Hirano S., Sasajima J., Kitano Y., Yanagawa N., Matsumoto K., Tanno S., Imamura M., Shitani M., Takahashi M., Miyakawa H., Nakamura F., Ambo Y., Kamachi H., Taketomi A.
Scientific Reports 12 ( 1 ) 9966 2022年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Scientific Reports
Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. In a multicenter phase II trial, we investigated the efficacy of Nac S-1 (an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium) in R-PDAC patients. The protocol involved two cycles of preoperative S-1 chemotherapy, followed by surgery, and four cycles of postoperative S-1 chemotherapy. Two-year progression-free survival (PFS) rates were the primary endpoint. Overall survival (OS) rates and median survival time (MST) were secondary endpoints. Forty-nine patients were eligible, and 31 patients underwent resection following Nac, as per protocol (31/49; 63.3%). Per-protocol analysis included data from 31 patients, yielding the 2-year PFS rate of 58.1%, and 2-, 3-, and 5-year OS rates of 96.8%, 54.8%, and 44.0%, respectively. MST was 49.2 months. Intention-to-treat analysis involved 49 patients, yielding the 2-year PFS rate of 40.8%, and the 2-, 3-, and 5-year OS rates of 87.8%, 46.9%, and 33.9%, respectively. MST was 35.5 months. S-1 single regimen might be an option for Nac in R-PDAC; however, the high drop-out rate (36.7%) was a limitation of this study.
-
Komaki Y., Ozono Y., Nakamura K., Iwakiri H., Hasuike S., Sueta M., Miike T., Yamamoto S., Uto H., Kusumoto K., Ochiai T., Kato J., Komada N., Kuroki K., Eto T., Shigehira M., Hirono S., Nagata K., Kawakami H.
BMC Gastroenterology 22 ( 1 ) 210 2022年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：BMC Gastroenterology
Background: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥ 75 years. Methods: This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G/P treatment were collected from medical records. The patients were divided into two groups: younger (n = 199, aged < 75 years) and older (n = 72, aged ≥ 75 years). Virological data and AEs were analyzed according to the age group. Results: In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (P = 0.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups. Conclusions: Compared with younger patients, older patients showed similar virological response and tolerance to G/P treatment.
-
Kitano M., Yoshida M., Ashida R., Kita E., Katanuma A., Itoi T., Mikata R., Nishikawa K., Matsubayashi H., Takayama Y., Kato H., Takenaka M., Ueki T., Kawashima Y., Nakai Y., Hashimoto S., Shigekawa M., Nebiki H., Tsumura H., Okabe Y., Ryozawa S., Harada Y., Mitoro A., Sasaki T., Yasuda H., Miura N., Ikemoto T., Ozawa E., Shioji K., Yamaguchi A., Okuzono T., Moriyama I., Hisai H., Fujita K., Goto T., Shirahata N., Iwata Y., Okabe Y., Hara K., Hashimoto Y., Kuwatani M., Isayama H., Fujimori N., Masamune A., Hatamaru K., Shimokawa T., Okazaki K., Takeyama Y., Yamaue H., Abue M., Aiura K., Akashi T., Akiyama T., Aoyagi H., Araki M., Arizumi T., Aruga Y., Asada M., Asai S., Baba T., Ban S., Chinen K., Doi S., Eguchi T., Endo M., Endo S., Ezaki T., Fujii K., Fujii M., Fujimori M., Fujimoto Y., Fujita Y., Fujita Y., Fukasawa M., Fukuba N., Fukuchi S., Fukuda K., Furukawa M., Furumatsu K., Hakamada K., Hanada K., Harada K., Harano M., Hashigo S., Hashiguchi K., Hayashi K., Hayashi N., Hayatsu S., Hijioka S., Hirano A., Hirao M., Hirooka Y., Hirota M., Horino K., Hotta Y., Ijima M., Ikuta Y., Imakiire K., Imamura T., Inatomi O.
Digestive Endoscopy 34 ( 7 ) 1442 - 1455 2022年11月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Digestive Endoscopy
Objectives: Endoscopic ultrasound-guided tissue acquisition (EUS-TA) plays a crucial role in the diagnosis of pancreatic tumors. The present study aimed to investigate the current status of needle tract seeding (NTS) after EUS-TA of pancreatic tumors based on a nationwide survey in Japan. Methods: Patients who underwent surgical resection of primary pancreatic tumors after EUS-TA performed between April 2010 and March 2018 were surveyed. The incidence rates of NTS were determined, and compared in patients with pancreatic ductal adenocarcinomas (PDACs) and other tumors, and in patients who underwent transgastric and transduodenal EUS-TA of PDACs. The detailed features and prognosis of patients with NTS were also assessed. Results: A total of 12,109 patients underwent surgical resection of primary pancreatic tumors after EUS-TA. The overall incidence rate of NTS was 0.330%, and the NTS rate was significantly higher in patients with PDAC than in those with other tumors (0.409% vs. 0.071%, P = 0.004). NTS was observed in 0.857% of patients who underwent transgastric EUS-TA, but in none of those who underwent transduodenal EUS-TA. Of the patients with NTS of PDACs, the median time from EUS-TA to occurrence of NTS and median patient survival were 19.3 and 44.7 months, respectively, with 97.4% of NTS located in the gastric wall and 65.8% of NTS resected. The patient survival was significantly longer in patients who underwent NTS resection than in those without NTS resection (P = 0.037). Conclusions: Needle tract seeding appeared only after transgastric not after transduodenal EUS-TA. Careful follow-up provides an opportunity to remove localized NTS lesions by gastrectomy.
DOI： 10.1111/den.14346
-
Mandai K., Tsuchiya T., Kawakami H., Ryozawa S., Saitou M., Iwai T., Ogawa T., Tamura T., Doi S., Okabe Y., Chiba Y., Itoi T.
Journal of Hepato-Biliary-Pancreatic Sciences 29 ( 11 ) 1185 - 1194 2022年11月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Hepato-Biliary-Pancreatic Sciences
Background/Purpose: Whether a fully covered self-expanding metal stent (FCSEMS) or plastic stent (PS) is preferable for preoperative biliary drainage in patients with resectable pancreatic cancer (RPC) is controversial. This study aimed to evaluate the safety and efficacy of drainage with FCSEMS for obstructive jaundice caused by RPC without neoadjuvant chemotherapy. Methods: Seventy patients with RPC who required preoperative biliary drainage were randomly assigned 1:1 to the FCSEMS or PS group. The primary endpoint was endoscopic re-intervention rate during the waiting period for surgery. Secondary endpoints were drainage procedure time, drainage-related adverse events (AE), waiting period for surgery, operative time, intraoperative blood loss, surgery-related AE, and postoperative hospital stay. Results: Thirty-nine patients underwent surgery. None required re-intervention in the FCSEMS group, whereas five PS patients underwent re-intervention (P =.023). The FCSEMS group had significantly more intraoperative blood loss (P =.0068) and AE (P =.011) than the PS group. Postoperative hospital stay was significantly longer in the FCSEMS group (P =.016). Conclusions: Fully covered self-expanding metal stent had a lower rate of endoscopic re-intervention during the waiting period for surgery than PS, but showed more intraoperative blood loss, higher incidence of surgery-related AE, and longer postoperative hospital stays.
DOI： 10.1002/jhbp.1090
-
特集 胃疾患アトラス 改訂版 各論 Ⅲ. 陥凹を呈する病変 1. 上皮性･非腫瘍性陥凹病変 胃Dieulafoy潰瘍
山本 章二朗, 三池 忠, 河上 洋
消化器内視鏡 34 ( 13 ) 194 - 195 2022年10月
-
Uchida K., Ozono Y., Uchiyama N., Hatada H., Nakamura K., Komaki Y., Iwakiri H., Hasuike S., Nagata K., Sato Y., Kawakami H.
Medicine (United States) 101 ( 35 ) e30486 2022年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Medicine (United States)
Rationale: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC. Patient concerns: A 73-year-old Japanese man diagnosed with a large HCC was treated with atezolizumab plus bevacizumab. After 2 cycles, he had fever and fatigue and was admitted to the hospital. Diagnosis: Abdominal contrast-enhanced computed tomography revealed tumor necrosis in HCC with gas formation in the necrotic area. Laboratory examination revealed a white blood cell (WBC) count of 16,340/μL and C-reactive protein (CRP) level of 33.0 mg/dL. Based on the above findings, he was diagnosed with a liver abscess. Interventions: Percutaneous transhepatic liver abscess drainage and broad-spectrum antibiotics treatment were performed. Outcomes: Despite liver abscess drainage, persistent fever and no improvement in the WBC count or CRP level was observed. The patient's respiratory condition and renal function gradually worsened; The patient's general condition did not improve despite the ventilator support and continuous hemodiafiltration, and he died on day 37. Lessons: We report the first case of liver abscess after atezolizumab plus bevacizumab treatment for unresectable HCC.
-
特集 胆道ドレナージのすべて-適応･方法 2.各論(7)経皮的胆囊ドレナージ
河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 田村 穂高, 大園 芳範
臨床消化器内科 37 ( 10 ) 1342 - 1349 2022年8月
-
特集 肝門部領域胆管ドレナージを極める [各論] 肝門部領域胆管狭窄に対するENBD
河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 内田 圭祐, 田村 穂高, 吉田 直樹, 市成 直樹, 大園 芳範
消化器内視鏡 34 ( 6 ) 1079 - 1083 2022年6月
-
Kato S., Kuwatani M., Onodera M., Kudo T., Sano I., Katanuma A., Uebayashi M., Eto K., Fukasawa M., Hashigo S., Iwashita T., Yoshida M., Taya Y., Kawakami H., Kato H., Nakai Y., Kobashigawa K., Kawahata S., Shinoura S., Ito K., Kubo K., Yamato H., Hara K., Maetani I., Mukai T., Shibukawa G., Itoi T.
Clinical Gastroenterology and Hepatology 20 ( 6 ) 1394 - 1403.e1 2022年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Clinical Gastroenterology and Hepatology
Background & Aims: The efficacy of endoscopic sphincterotomy (ES) before endoscopic transpapillary biliary drainage in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been established. The aim of this study was to evaluate the effect of performing ES before biliary stent/tube placement on the occurrence of PEP. Methods: Three hundred seventy patients with biliary stricture requiring endoscopic biliary stenting were enrolled and randomly allocated to the ES group (n = 185) or non-ES group (n = 185). All participants were followed up for 30 days after the procedure. The data and occurrence of adverse events were prospectively collected. The primary outcome measure of this study was the incidence of PEP within 2 days of initial transpapillary biliary drainage. Secondary outcome measures were the incidence of other adverse events related to biliary stent/tube placement. Results: PEP occurred in 36 patients (20.6%) in the non-ES group and in 7 patients (3.9%) in the ES group (P < .001). The difference in the incidence of PEP between the 2 groups in the per-protocol population was 16.7% (95% confidence interval, 10.1%–23.3%), which was not within the noninferiority margin of 6%. Except for bleeding, the incidences of other adverse events were not significantly different between the groups. Conclusion: ES before endoscopic biliary stenting could have the preventive effect on the occurrence of PEP in patients with biliary stricture. University Hospital Medical Information Network Number, UMIN000025727.University Hospital Medical Information Network Clinical Trial Registry URL: https://www.umin.ac.jp/ctr/index.htm
-
Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency. 査読あり
Tamura H, Nakashima K, Uchiyama N, Ogawa S, Hatada H, Yoshida N, Uchida K, Ozono Y, Tanaka H, Yamamto K, Kawakami H
Internal medicine (Tokyo, Japan) 61 ( 10 ) 1503 - 1509 2022年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本内科学会
Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent <i>KRAS/NRAS/BRAF</i> wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.
-
EUS-GUIDED BILIARY AND JEJUNAL DRAINAGE FOR RECURRENT GALLBLADDER CANCER: A CASE REPORT
Uchiyama N., Kawakami H., Kubota Y., Hatada H., Ogawa S., Tamura H., Yoshida N.
Gastroenterological Endoscopy 64 ( 3 ) 270 - 276 2022年3月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Gastroenterological Endoscopy
A 65-year-old man with small bowel obstruction (SBO) and obstructive jaundice due to recurrence of cystic duct cancer was admitted to our division. He had history of gallbladder bed and extrahepatic bile duct resection (partial liver resection) with Roux-en-Y reconstruction. We performed EUS-guided hepaticogastrostomy (EUS-HGS) for biliary drainage and EUS-guided transluminal drainage of dilated jejunal limb. Obstructive jaundice and abdominal pain were resolved, thereby improving the patient's QOL. We searched PubMed for articles published between October 2000 and October 2021 using the terms "EUS-guided transluminal drainage, gastrojejunostomy, or gastroenterostomy" and "small bowel obstruction". On the basis of search results, this is the first report on EUS-guided transmural drainage for SBO and jaundice due to recurrence of cystic duct cancer. It is difficult to improve prognosis and QOL of patients with SBO caused by recurrent cancer with surgical treatment. Thus, endoscopic internal drainage is desirable. In the future, the development of dedicated devices and elaborate indications for currently available devices are required.
DOI： 10.11280/gee.64.270